Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease:a Rapid Health Technology Assessment

OBJECTIVE To evaluate the effectiveness, safety and economy of the clinical use of roxadustat in the treatment of chronic kidney disease anemiausing rapid health technology assessment methods, and to provide evidence-based evidence for clinical rational use of drugs and selection of new drugs by medical institutions. METHODS PubMed, the Cochrane Library, Embase, CRD database, CNKI, Wanfang Data, Sinomed and related HTA website were systematically searched to collect systematic reviews from inception to October 2020. Two reviewers independently identified according to the inclusion criteria, extracted data and assessed quality of includedstudies. Qualitative analysis were performed. RESULTS Four systematic reviews/meta analysis and one pharmacoeconomic studies were included. Compared with placebo, roxadustat could increase hemoglobin levels, reduce the hepcidin, and increase total iron binding capacity and transferrin in non-dialysis- dependent chronic kidney disease patients. Compared with erythropoiesis-stimulatingagents, it improved total iron binding capacity and hemoglobin levels in patients with dialysis-dependent chronic kidney disease, and down-regulated ferritin and hepcidin. Domestic economic model research showed that roxadustat had a cost-effective advantage.CONCLUSION Roxastat has good efficacy and safety. Compared with placebo, roxadustat has a certain economic efficiency, and further economic research should be carried out.